Other languages Alligator Bioscience AB London S.E.

Equities

0RK9

SE0000767188

Market Closed - London S.E. Other stock markets 09:22:01 17/11/2021 pm IST			5-day change	1st Jan Change
2.508 ^SEK	-66.28%		+123.96%	+303.28%

14/05	Alligator Bioscience Announces Initiation of an Investigator-Initiated Phase 1 Clinical Study of Mitazalimab in Local Advanced Pancreatic Cancer	CI
06/05	Transcript : Alligator Bioscience AB, Q1 2024 Earnings Call, May 06, 2024

Other languages

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Alligator Bioscience Announces Initiation of an Investigator-Initiated Phase 1 Clinical Study of Mitazalimab in Local Advanced Pancreatic Cancer	14/05
Alligator Bioscience AB Reports Earnings Results for the First Quarter Ended March 31, 2024	06/05
Alligator Bioscience and Orion Corporation Announces Exercise of Development Option Under 2021 Research Collaboration and License Agreement	26/04
Alligator Bioscience AB Announces Graham Dixon and Veronica Wallin Not Proposed for Re-Election on Board	05/04
Alligator Bioscience Announces Publication of a Scientific Article Featuring Its Novel Bispecific Antibody Format RUBY® in the Peer-Reviewed Journal mAbs	26/03
Alligator Bioscience and Aptevo Therapeutics Announce Positive Interim Data of Dose Escalation Phase of ALG.APV-527 Phase 1 Study in Solid Tumor Cancers Expressing Tumor Antigen 5T4	07/03
Correction: Alligator Bioscience Seeks SEK151 Million Capital Raising, Enters SEK59 Million Bridge Loan	09/02
Alligator Bioscience Seeks SEK151 Capital Raising, Enters SEK59 Million Bridge Loan	09/02
Alligator Bioscience to Trim Workforce Amid Restructuring Program	08/02
Alligator Bioscience AB Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023	08/02
Alligator Bioscience Plans to Adjust Size of Organization with Reduction of Approximately 20% to 25% of Current Workforce	08/02
Alligator Bioscience Announces Positive Top-Line Results from the Optimize-1 Phase 2 Study of the Company's Lead Asset Mitazalimab in 1st Line Metastatic Pancreatic Cancer	29/01
Alligator Bioscience Secures US Patent for Cancer Treatment Antibody	16/01
Alligator Bioscience AB Appoints Bertil Brinck as Chairman of the Nomination Committee	06/11
Alligator Bioscience AB Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	26/23/26
Alligator Bioscience Grants New Composition of Matter Patent in Europe for Mitazalimab	12/23/12
Alligator Bioscience Chief Operating Officer to Resign	17/23/17
Alligator Bioscience AB Announces Resignation of Malin Carlsson as Chief Operating Officer At the End of October	17/23/17
Alligator Bioscience Advances Research Partnership With Orion	31/23/31
Alligator Bioscience AB Announces Technical Feasibility in the Second Program Under the Research Collaboration and License Agreement with Orion Corporation	31/23/31

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Other languages Alligator Bioscience AB London S.E.

Equities

0RK9

SE0000767188

Other languages

Filters